Last reviewed · How we verify
Cold autoimmune hemolytic anemia
Approved treatments
- Enjaymo · Bioverativ Therapeutics Inc
Enjaymo works by blocking the activity of the complement C1s subcomponent, a part of the immune system that can mistakenly attack red blood cells. - ENJAYMO · RECORDATI RARE DISEASES, INC.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cold autoimmune hemolytic anemia patent landscape — cliff calendar, originator estates, attackable patents
- Cold autoimmune hemolytic anemia treatment landscape brief
- Cold autoimmune hemolytic anemia treatment updates RSS
Frequently asked questions about Cold autoimmune hemolytic anemia
What drugs treat Cold autoimmune hemolytic anemia?
Tracked treatments include Enjaymo, ENJAYMO.
What is the treatment for Cold autoimmune hemolytic anemia?
Standard treatment for Cold autoimmune hemolytic anemia includes Enjaymo, ENJAYMO. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cold autoimmune hemolytic anemia patent cliff · Cold autoimmune hemolytic anemia CI report
- Treatment: Enjaymo · Bioverativ Therapeutics Inc
- Treatment: ENJAYMO · RECORDATI RARE DISEASES, INC.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing